| 65.25 0.4 (0.62%) | 12-04 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 80.79 | 1-year : | 94.36 |
| Resists | First : | 69.16 | Second : | 80.79 |
| Pivot price | 61.51  |
|||
| Supports | First : | 59.86 | Second : | 54.11 |
| MAs | MA(5) : | 64.3 |
MA(20) : | 60.41 |
| MA(100) : | 71.6  |
MA(250) : | 0 | |
| MACD | MACD : | 0.1 |
Signal : | -0.9 |
| %K %D | K(14,3) : | 94.7 |
D(3) : | 93.8 |
| RSI | RSI(14): 58.5 |
|||
| 52-week | High : | 93.25 | Low : | 54.11 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ DXCM ] has closed below upper band by 10.5%. Bollinger Bands are 17.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 65.37 - 65.57 | 65.57 - 65.78 |
| Low: | 63.5 - 63.74 | 63.74 - 64 |
| Close: | 64.83 - 65.19 | 65.19 - 65.59 |
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Fri, 05 Dec 2025
DexCom, Inc. $DXCM Shares Acquired by Marshall Wace LLP - MarketBeat
Thu, 04 Dec 2025
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
Thu, 04 Dec 2025
DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser - ACCESS Newswire
Thu, 04 Dec 2025
Dexcom (NASDAQ: DXCM) rolls out Dexcom Academy CGM education for HCPs in 5 countries - Stock Titan
Thu, 04 Dec 2025
Sands Capital Management LLC Decreases Position in DexCom, Inc. $DXCM - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 390 (M) |
| Shares Float | 387 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 99.5 (%) |
| Shares Short | 13,410 (K) |
| Shares Short P.Month | 11,620 (K) |
| EPS | 1.79 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.98 |
| Profit Margin | 15.9 % |
| Operating Margin | 20 % |
| Return on Assets (ttm) | 7 % |
| Return on Equity (ttm) | 30.6 % |
| Qtrly Rev. Growth | 21.6 % |
| Gross Profit (p.s.) | 6.82 |
| Sales Per Share | 11.58 |
| EBITDA (p.s.) | 2.61 |
| Qtrly Earnings Growth | 109.9 % |
| Operating Cash Flow | 1,450 (M) |
| Levered Free Cash Flow | 783 (M) |
| PE Ratio | 36.25 |
| PEG Ratio | 0 |
| Price to Book value | 9.33 |
| Price to Sales | 5.63 |
| Price to Cash Flow | 17.55 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|